RecruitingNot Applicable

NOX4 and Related Biomarkers in ADPKD

United States60 participantsStarted 2020-07-21

Plain-language summary

To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).

Who can participate

Age range15 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ADPKD (based on Ravine et al. criteria) * Class 1 A-E according to imaging classification * Male and female subjects 15 - 40 years of age * Estimated GFR\> 70 mL/min/1.73 m2 (CKD-EPI) * Ability to provide written, informed consent Exclusion Criteria: * Class 2 according to imaging classification * Concomitant systemic disease affecting the kidney * Diabetes mellitus * Predicted urine protein excretion in \>1 g/24 hrs * Use of antioxidants i.e. vitamins, Nrf2 activators * Abnormal urinalysis

What they're measuring

NOX4 levels

Timeframe: Baseline

mtDNA copy number

Timeframe: Baseline

Tricarboxylic Acid (TCA) cycle metabolites

Timeframe: Baseline

REDOX status

Timeframe: Baseline

Total kidney volume (TKV)

Timeframe: Baseline

Trial details

NCT IDNCT04630613

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Autosomal Dominant Polycystic Kidney Disease trials